Key result
Rheumatoid arthritis (with and without DMARDs) and mild psoriasis were associated with significantly elevated risks of venous thromboembolism compared to controls (HR 1.35, 1.29, and 1.07).
Why the study?
Does the presence of inflammatory disorders (psoriatic arthritis, rheumatoid arthritis, psoriasis) increase the risk of venous thromboembolism compared to population controls?
Cohort (n=1,483,705)
Does the presence of inflammatory disorders (psoriatic arthritis, rheumatoid arthritis, psoriasis) increase the risk of venous thromboembolism compared to population controls?
Effect estimate: HR 1.35, 1.29, and 1.07
Patients with rheumatoid arthritis and mild psoriasis have a significantly elevated risk of venous thromboembolism compared to the general population, highlighting the role of systemic inflammation in VTE risk.
No takes yet. Share an insight, caveat, or question.
May support heightened VTE vigilance in RA and psoriasis; leaves open whether anti-inflammatory therapies reduce this risk.
Ogdie et al. (2017) conducted a cohort in Psoriatic arthritis, psoriasis, and rheumatoid arthritis (n=1,483,705). Psoriatic arthritis, psoriasis, and rheumatoid arthritis vs. Matched general population controls was evaluated on Venous thromboembolism (combined endpoint of deep venous thrombosis and pulmonary embolism) (HR 1.35, 1.29, and 1.07). Rheumatoid arthritis (with and without DMARDs) and mild psoriasis were associated with significantly elevated risks of venous thromboembolism compared to controls (HR 1.35, 1.29, and 1.07).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: